New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 10, 2014
07:21 EDTICPTIntercept price target raised to $493 from $449 at Wedbush
Wedbush raised its price target for Intercept Pharmaceuticals shares to $493 saying a new Phase 2 clinical study for OCA in alcoholic hepatitis increases the company's acquisition value. The firm reiterates an Outperform rating on the stock.
News For ICPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 3, 2015
07:35 EDTICPTIntercept risk/reward positive, says RBC Capital
RBC Capital believes that Intercept will rally 20% or more if GenFit data, expected to be announced in the second half of March, isn't clean. If the GenFit data is positive, Intercept's stock might drop, but it would probably rebound, since the company would probably reach a deal with the FDA on a Phase III trial of its OCA drug soon thereafter, according to the firm. RBC keeps a $490 price target and Outperform rating on Intercept.
March 2, 2015
06:13 EDTICPTIntercept reports Q4 EPS ($1.63), consensus ($1.67)
Subscribe for More Information
February 19, 2015
16:31 EDTICPTIntercept promotes Lisa Bright to Chief Commercial & Corporate Affairs Officer
Intercept Pharmaceuticals announced that Lisa Bright has been promoted to the newly-created position of Chief Commercial and Corporate Affairs Officer. Bright joined Intercept last year from Gilead Sciences where her leadership of the European launch of Sovaldi for the treatment of chronic hepatitis C contributed to the most successful product launch in pharmaceutical history.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use